Changes in Hong Kong stocks | Hanson Pharmaceuticals (03692) rose nearly 3% in the afternoon HS-10582 tablets received a drug clinical trial approval notice issued by NMPA

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Hanson Pharmaceuticals (03692) rose nearly 3% in the afternoon. As of press release, it had risen 2.27% to HK$32.4, with a turnover of HK$136 million.

According to the news, Hanson Pharmaceuticals announced that the new Class 1 drug HS-10582 tablets independently developed by the Group have received a drug clinical trial approval notice issued by the China National Drug Administration (NMPA) to carry out clinical trials for “treating essential hypercholesterolemia and mixed dyslipidemia in adults”.